[EN] NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF<br/>[FR] NOUVELLES N-ACYL-5,6,7,8-TÉTRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZINES 8-SUBSTITUÉES CHIRALES UTILISÉES COMME ANTAGONISTES SÉLECTIFS DES RÉCEPTEURS NK-3, COMPOSITION PHARMACEUTIQUE, PROCÉDÉS DESTINÉS À ÊTRE UTILISÉS DANS DES TROUBLES À MÉDIATION PAR LE RÉCEPTEUR NK-3 ET LEUR SYNTHÈSE CHIRALE
申请人:EUROSCREEN SA
公开号:WO2013050424A1
公开(公告)日:2013-04-11
The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.
本发明涉及公式I的新化合物及其在治疗治疗中的应用。该发明还涉及使用N-sp3保护基对5,6,7,(8-取代)-四氢-[1,2,4]三唑并[4,3-a]吡嗪进行新的手性合成。该发明还提供了用于合成公式I化合物的中间体。
Design and Elaboration of a Tractable Tricyclic Scaffold To Synthesize Druglike Inhibitors of Dipeptidyl Peptidase-4 (DPP-4), Antagonists of the C–C Chemokine Receptor Type 5 (CCR5), and Highly Potent and Selective Phosphoinositol-3 Kinase δ (PI3Kδ) Inhibitors
作者:Carolin Schwehm、Barrie Kellam、Aimie E. Garces、Stephen J. Hill、Nicholas D. Kindon、Tracey D. Bradshaw、Jin Li、Simon J. F. Macdonald、James E. Rowedder、Leigh A. Stoddart、Michael J. Stocks
DOI:10.1021/acs.jmedchem.6b01801
日期:2017.2.23
novel molecular scaffold has been synthesized, and its incorporation into new analogues of biologically active molecules across multiple target classes will be discussed. In these studies, we have shown use of the tricyclic scaffold to synthesize potent inhibitors of the serine peptidase DPP-4, antagonists of the CCR5 receptor, and highly potent and selective PI3K δ isoform inhibitors. We also describe
已经合成了新型分子支架,并将讨论其如何结合到跨多个靶类别的生物活性分子的新类似物中。在这些研究中,我们显示了使用三环支架合成丝氨酸肽酶DPP-4的有效抑制剂,CCR5受体的拮抗剂以及高效且选择性的PI3Kδ同工型抑制剂。我们还描述了所得抑制剂的预测理化性质,并得出结论,该易处理的分子支架可能在未来的药物开发计划中具有潜在的应用。